Efficacy of ART to Interrupt HIV Transmission Networks (ART-NET)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02528773|
Recruitment Status : Recruiting
First Posted : August 19, 2015
Last Update Posted : July 12, 2018
|Condition or disease|
|Study Type :||Observational|
|Estimated Enrollment :||425 participants|
|Official Title:||Efficacy of ART to Interrupt HIV Transmission Networks|
|Study Start Date :||October 2014|
|Estimated Primary Completion Date :||October 2019|
|Estimated Study Completion Date :||October 2020|
Persons newly diagnosed with HIV.
- Network-level efficacy of ART as measured by the number of newly infected persons and network cluster growth over time [ Time Frame: 5 Years ]
Biospecimen Retention: Samples With DNA
Blood Draws: Approximately 2 tablespoons (30 mL) of blood will be taken for blood tests and storage at each visit. Participants' blood will be tested for:
- CD4+/CD8+ T-cell Count. This is a measure of the immune system; T-cells help the immune system fight infections.
- HIV-1 RNA (Viral Load). This measures the amount of HIV in the blood.
- HIV pol sequence. This measures the type of HIV in your blood.
- Blood will be collected for storage for future HIV testing, studies to measure the amount of residual HIV that remains in people who are doing well on HIV treatment, genetic testing of the HIV virus and possible HLA genotype testing as determined by the results of this and future studies.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02528773
|Contact: Jill Kunkel, RNfirstname.lastname@example.org|
|United States, California|
|UCSD AntiViral Research Center||Recruiting|
|San Diego, California, United States, 92103|
|Contact: Liliana Ramirez 619-543-8080 email@example.com|
|Principal Investigator:||Susan J Little, MD||UCSD|